(Q34065752)

30 July 2017

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion (English)

1 reference

30 July 2017

1 reference

Guevara M

1

1 reference

30 July 2017

Ginès P

2

1 reference

30 July 2017

Fernández-Esparrach G

3

1 reference

30 July 2017

Sort P

4

1 reference

30 July 2017

Salmerón JM

5

1 reference

30 July 2017

Jiménez W

6

1 reference

30 July 2017

Arroyo V

7

1 reference

30 July 2017

Rodés J

8

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

30 July 2017

1 reference

30 July 2017

27

1 reference

30 July 2017

1

1 reference

30 July 2017

35-41

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

30 July 2017

1 reference

7 January 2021

Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.510270107

1 reference

7 January 2021

Pathogenesis and management of the hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Vasopressin analogues with selective pressor activity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Some cardiovascular effects of ornithine-8-vasopressin: a new surgical vasoconstrictor agent

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

A new method for the determination of inulin in plasma and urine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Tongue necrosis after intraarterial vasopressin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Drug therapy for portal hypertension.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Dose-response relation of ornipressin with regard to vasoconstriction in human skin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Vasoconstrictors and general anaesthesia. Ornithine-8-vasopressin and noradrenaline during halothane anaesthesia in a double-blind study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Systemic and Renal Hemodynamics in Oliguric Hepatic Failure: Effect of Volume Expansion*

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Glomerular hyperfiltration after protein ingestion, during glucagon infusion, and in insulin-dependent diabetes is induced by a liver hormone: deficient production of this hormone in hepatic failure causes hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Sodium excretion in advanced cirrhosis: effect of expansion of central blood volume and suppression of plasma aldosterone

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Paracrine regulation of the renal microcirculation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Glomerular actions of endothelin in vivo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Amelioration of hepatorenal syndrome with selective endothelin-A antagonist

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Continuous intravenous vasopressin in active upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270107

7 January 2021

Identifiers

DOI

10.1002/HEP.510270107

1 reference

30 July 2017

1 reference